Menu Search
Equities

Mabwell Shanghai Bioscience Co Ltd

688062:SHH

Mabwell Shanghai Bioscience Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)21.19
  • Today's Change-2.02 / -8.70%
  • Shares traded9.46m
  • 1 Year change-25.65%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Mabwell Shanghai Bioscience Co Ltd had net income fall 10.28% from a loss of 955.23m to a larger loss of 1.05bn despite a 361.03% increase in revenues from 27.73m to 127.84m.
Gross margin90.50%
Net profit margin-636.41%
Operating margin-631.27%
Return on assets-24.10%
Return on equity-44.39%
Return on investment-30.74%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Mabwell Shanghai Bioscience Co Ltd fell by 846.01m. Cash Flow from Financing totalled 444.94m or 348.05% of revenues. In addition the company used 782.73m for operations while cash used for investing totalled 509.62m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.80
Tangible book value per share4.14
More ▼

Balance sheet in CNYView more

Mabwell Shanghai Bioscience Co Ltd has a Debt to Total Capital ratio of 53.39%, a higher figure than the previous year's 34.70%.
Current ratio1.40
Quick ratio1.25
Total debt/total equity1.14
Total debt/total capital0.5339
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.